{{medical}}
{{Drugbox
| verifiedrevid = 456683223
| IUPAC_name = adamantan-1-amine
| image = Amantadine2DCSD.svg
| width = 150
| image2 = Adamantadine-3D-balls.png
<!--Clinical data-->
| tradename = Symmetrel
| Drugs.com = {{drugs.com|monograph|amantadine-hydrochloride}}
| MedlinePlus = a682064
| pregnancy_AU = B3
| pregnancy_US = C
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = 口服
<!--Pharmacokinetic data-->
| bioavailability = 86-90%<ref name = TGA>{{cite web|title=SYMMETREL® (amantadine hydrochloride)|work=TGA eBusiness Services|publisher=NOVARTIS Pharmaceuticals Australia Pty Limited|date=29 June 2011|accessdate=24 February 2014|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04197-3|format=PDF}}</ref>

| protein_bound = 67%<ref name = TGA/>
| metabolism = 极少 (大部分转化为乙酰代谢物)<ref name = TGA/>
| elimination_half-life = 10-31 小时<ref name = TGA/>
| excretion = 尿液<ref name = TGA/>
<!--Identifiers-->
| IUPHAR_ligand = 4128
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 768-94-5
| ATC_prefix = N04
| ATC_suffix = BB01
| PubChem = 2130
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00915
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2045
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = BF4C9Z1J53
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07441
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 2618
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 660
<!--Chemical data-->
| C=10 | H=17
| N=1
| molecular_weight = 151.249 g/mol
| smiles = NC13CC2CC(CC(C1)C2)C3
| InChI = 1/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2
| InChIKey = DKNWSYNQZKUICI-UHFFFAOYAJ
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = DKNWSYNQZKUICI-UHFFFAOYSA-N
| synonyms = 1-Adamantylamine
}}

'''金刚烷胺'''（{{lang-en|Amantadine}}，常用名'''金刚胺'''）是美国[[FDA|FDA]]所批准的抗病毒和抗帕金森病药。[[金刚乙胺|金刚乙胺]]与金刚烷胺有着相似的结构和性质。

根据[[美国疾病控制与预防中心|美国疾病控制与预防中心]]的数据，100%的季节性[[H3N2|H3N2]]流感和[[2009年H1N1流感大流行|2009年H1N1流感大流行]]的流感病毒样本对金刚烷胺有[[耐药性|耐药性]]。在美国，金刚烷胺不再被推荐作为[[感冒药|感冒药]]。另外，金刚烷胺抗[[帕金森病|帕金森病]]的效果仍不确定，2003年[[考科藍|考科藍]]指出没有充分的证据证明金刚烷胺抗帕金森病的效果和安全性。<ref name="Cochrane report">{{cite journal | doi = 10.1002/14651858.CD003468 | title = Amantadine in Parkinson's disease | journal = Cochrane Database of Systematic Reviews | year = 2003 | last1 = Crosby | first1 = Niall J | last2 = Deane | first2 = Katherine | last3 = Clarke | first3 = Carl E | editor1-last = Clarke | editor1-first = Carl E}}</ref>

==参见==
* [[金刚烷|金刚烷]]

==引用==
{{reflist}}

{{Influenza}}
{{Sigmaergics}}
{{ADHD_pharmacotherapies}}
{{RNA antivirals|state=autocollapse}}

[[Category:伯胺|Category:伯胺]]
[[Category:抗RNA病毒药物|Category:抗RNA病毒药物]]
[[Category:金刚烷基化合物|Category:金刚烷基化合物]]